Breaking Business News: Crown Laboratories to Buy Revance Therapeutics in $924 Million Merger Deal
The Dermatology Digest
AUGUST 12, 2024
The purchase price represents a premium of 89% over Revance’s closing market price on August 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price. Crown shares our commitment to innovation and scale and will help us accelerate our growth. ” Mark J.
Let's personalize your content